Arab Press

بالشعب و للشعب
Monday, Apr 06, 2026

Pfizer’s obscene $900m profit from its Covid vaccine in just three months proves capitalism and public health are bad bedfellows

Pfizer’s obscene $900m profit from its Covid vaccine in just three months proves capitalism and public health are bad bedfellows

The US pharmaceutical giant cashing in on a pandemic that has killed 3.2m people while failing to help the world’s poor is morally indefensible, and illustrates the corrupt nature of monopoly medicine.
As the New York Times reported, Pfizer generated hundreds of millions in profits in the first quarter of 2021, thanks to its successful Covid-19 vaccine. What’s interesting about the company’s success, however, is that its vaccine is one of just two widely used that are produced on a for-profit basis – and the only one whose manufacturer is not reliant on it to stay afloat. Pfizer’s windfall this year is, in essence, a windfall for monopoly medicine.

Unlike its Western competitors Johnson & Johnson and AstraZeneca, Pfizer decided early to profit from its vaccine. That profit margin hasn’t been disclosed, but it was predicted that this would be in the high 20% range. That means that, of the $3.5 billion brought in by the vaccine this quarter, about $900m is pre-tax profit.

Unlike Moderna, a competitor that uses similar vaccine technology to Pfizer’s, Pfizer is an extraordinarily profitable company already, making $9.6 billion in profits in 2020 before the vaccine had even had a serious impact. Moderna has no other products on the market, so turning a profit on its vaccine is crucial for its operation. Not so for Pfizer.

Pfizer sells its vaccine sales at different rates. The United States, for example, pays $19.50 for each dose, while Israel has reportedly paid $30.The reason all this is morally justifiable, Pfizer has said repeatedly, is that it was never part of the US government’s Operation Warp Speed and therefore should be allowed to set its own prices.

However, this is deceptive. BioNTech, the company that actually developed the vaccine, after which Pfizer basically slapped its label on it, received a $455 million grant from the German government and got around $6 billion in purchase commitments from the US and EU. Not only that, but the Pfizer vaccine is based on mRNA technology patented by the National Institutes of Health that was funded by US taxpayers.

In a nutshell, Pfizer capitalized on a partnership with a then-obscure German biotech company that received German government grants to develop its vaccine based on US taxpayer-funded technology, and then received purchasing guarantees from rich governments that guaranteed billions of dollars in revenue. It managed to privatize all the profits while socializing all the risk in what was a textbook case of how corrupt Big Pharma is.

But the scope of this monumental corruption really shines through when you consider that this is a once-in-several-lifetimes public health emergency that has killed millions of people. Governments around the world promised a warlike response to the Covid-19 pandemic and yet it’s mostly been just business as usual.

As I mentioned in my previous piece for RT on Bill Gates, global capitalism has reinforced itself through the pandemic, with Big Pharma being no exception. Intellectual property (IP) laws, which have only been defended in multilateral institutions such as the United Nations by rich countries, are demonstrably a barrier to getting vaccine doses out – and everyone knows it.

Even US President Joe Biden said on the campaign trail in 2020 that he would suspend IP rights to make vaccines more affordable around the globe.

“Absolutely, positively. This is the only humane thing in the world to do,” Biden said. (I’m sure the fact that Pfizer was among the companies that handed over a maximum $1 million donation to Biden’s inauguration had nothing to do with his about-face…)

But not only has IP been an issue, but even the general cost and logistics of transporting the Pfizer vaccine has proven a challenge for nations, especially poorer ones, that want to receive it. Yet, somehow, the Pfizer vaccine is emerging as the predominant Covid-19 vaccine shipped by Western countries, while lower-cost, less-intensive vaccines are being discredited.

Aside from the obvious fact that China’s vaccines or Russia’s Sputnik V are being refused for consideration, are being delayed for review by other countries, or are being conspiratorially attacked by Western media, there does seem to be some kind of bias in favor of Pfizer, even among Western vaccine-makers.

Consider that Oxford University published a study on April 15 showing that the risk of portal vein thrombosis (a blood clot in the liver) appears to be 30 times higher with the mRNA vaccines made by Moderna and Pfizer (that is, the two for-profit vaccines) than with AstraZeneca’s. Consider also that the risk of cerebral vein thrombosis (a blood clot in the brain) appears to be quite similar with both AstraZeneca (five in a million) and those mRNA vaccines (four in a million).

So, while blood-clotting concerns have caused controversy and even the discontinuation of vaccines made by AstraZeneca and Johnson & Johnson, any mention of this from mRNA vaccines in the media has been pretty much nonexistent. That’s quite strange.

Also, headlines trumpet all the time how highly effective Pfizer’s vaccine is, placing huge importance on the percentage of its effectiveness without adding context. As the Vox YouTube channel masterfully explained in a video posted in March, it’s extremely difficult to compare vaccines – especially as they’re being tested in different parts and at different times.

Pfizer’s chief executive promised to ensure that poorer countries “have the same access as the rest of the world” to its vaccine. But as of last month, wealthy nations had secured more than 87% of the more than 700 million doses of Covid-19 vaccines dispensed worldwide, while poorer countries had received only 0.2%, according to the World Health Organization.

Pfizer has pledged 40 million doses to Covax, the partnership aimed at supplying vaccines to poor countries. But, as the New York Times report points out, that’s less than 2% of the 2.5 billion doses it aims to produce this year.

Now, none of this is to say that Pfizer’s vaccine is not effective and you shouldn’t take it. I received the Pfizer vaccine and will get my second dose on Friday. The best vaccine is the one you have access to. But the problem is that Pfizer’s seems to be getting too much free exposure in the media, despite the fact it's expensive, difficult to transport, and held under IP protections, making it inaccessible to most people in the world right now.

Pfizer has successfully maneuvered our corrupt system to rake in record profits with virtually no risk at all. It’s sad to say, but this happens all the time. However, right now, it’s only artificially prolonging a once-in-a-century pandemic that, I think most of us can agree, is destroying our lives. Let Pfizer’s success this year be a historic reminder of why capitalism and public health are totally incompatible.
Newsletter

Related Articles

Arab Press
0:00
0:00
Close
Taiwan to Source Oil Shipments from Saudi Arabia’s Red Sea Ports
Saudi Arabia Evacuates Riyadh Financial District as Precaution Amid Regional Tensions
Saudi Arabia Balances Ambitious Economic Vision Amid Regional Tensions and Financial Pressures
Budget Saudi Arabia Reports Strong Full-Year 2025 Financial Performance
Saudi Arabia Expands Investment in Capcom With Stake Reaching Six Percent
Saudi Arabia Assesses Significant Economic Impact From Regional Conflict Involving Iran
US Beef Secures Expanded Market Access in Saudi Arabia
Jordan and Saudi Arabia Declare Absolute Solidarity in Response to Iranian Threats
Saudi Arabia Raises Oil Prices to Record Premium Amid Strong Market Demand
California’s Salton Sea Emerges as Strategic Lithium Hub for Clean Energy Future
Iranian Drone Strike on US Embassy in Saudi Arabia Reportedly Targeted Intelligence Facility
Saudi Deputy Foreign Minister Meets French Embassy Official to Strengthen Bilateral Engagement
Saudi Arabia Calls on United States to Seize Strategic Opportunity to Reshape Middle East
Dating Apps Surge in Saudi Arabia as Social Norms Rapidly Evolve Among Youth
Saudi Arabia Detains Over Fourteen Thousand Illegal Residents in Week-Long Enforcement Drive
Saudi Foreign Minister Engages in Diplomatic Talks with Pakistan, Kuwait and Latvia on Regional Developments
Saudi Arabia Intercepts Cruise Missile as Regional Tensions Intensify
Saudi Stock Market Edges Higher as Tadawul Index Records Modest Gain
Underlying Rivalry Between Saudi Arabia and UAE Persists Despite Temporary Calm
Saudi Arabia’s Non-Oil Sector Contracts in March as Regional Tensions Weigh on Business Activity
Saudi Arabia Unveils Ambition to Establish Prestigious Global Prize Rivaling the Nobel
Saudi Crown Prince to Engage Wall Street in Push for Investment and Economic Expansion
Iran Accuses Saudi Arabia and UAE After Downing of Chinese-Made Drone
Saudi Arabia Condemns Attack on Hospital in Sudan, Calls for Protection of Civilians
Coordinated Drone Strike Targets CIA Facility Within US Embassy in Saudi Arabia
Italy’s Meloni Prioritises Energy Security and Strait of Hormuz Stability During Gulf Tour
Uncertainty Emerges Over Timeline and Direction of Saudi Arabia’s Ambitious Ski Resort Project
UAE and Saudi Arabia Escalate Strategy with Drone Operations Targeting Iran
Trump Delivers Characteristic Remarks on Saudi Crown Prince Amid Intensifying Iran Conflict
Drone Strike on US Embassy in Riyadh Caused Greater Damage Than First Reported
Saudi Arabia Introduces Flexible Solutions for Expired Visas Amid Regional Disruptions
Saudi Arabia’s Online Car Market Accelerates with AI Pricing and Fully Digital Buying Experience
Saudi Arabia Reassesses Defence Strategy as Iranian Drone Threat Drives Shift in Military Partnerships
Drone Strikes Target Saudi Arabia, Kuwait and Bahrain as Regional Conflict Intensifies
Japan and Saudi Arabia Align Efforts to Ease Rising Tensions with Iran
Saudi Crown Prince and Italy’s Meloni Strengthen Strategic Ties in High-Level Talks
SpaceX Explores Potential Five Billion Dollar Investment from Saudi Sovereign Wealth Fund Ahead of IPO
Saudi Arabia Lifts Key Import Barriers to Expand Access for U.S. Beef Exports
Saudi Arabia Enforces Strict Travel Penalties for Visits to Restricted Countries
Italy’s Meloni Embarks on Strategic Gulf Tour to Address Energy Security and Regional Stability
Saudi Film Festival Rescheduled to Summer as Regional Tensions Continue
Saudi Arabia Reports Forty Two Point Six Billion Dollars in Foreign Tourist Spending in 2025
Saudi Crown Prince and Russian President Hold Strategic Call on Escalating Regional Crisis
Saudi Arabia Advances Rail Network as Strategic Alternative to Strait of Hormuz Shipping Route
Ruanyun Edai Launches Saudi Arabia Hub With Forecast of Ten Percent Revenue Growth
Greek Defence Minister Visits Troops in Saudi Arabia Following Successful Missile Interception
Saudi Arabia Expands Global Strategy With Focus on African Critical Minerals
SpaceX Explores Potential Five Billion Dollar Investment From Saudi Fund Ahead of Possible IPO
US Central Command Dismisses Iranian Claim of Mass Casualties Among American Personnel in Saudi Arabia
Co-Diagnostics to Establish Molecular Diagnostics Facility in Saudi Arabia Through Joint Venture
×